BioTime Stock: “Buy” Ratings Abound, Should You Take Note?

BioTime stock is currently selling for $1.18 USD on the NYSE American exchange. At the time of writing, shares are down nearly 5%. Despite a rough few trading days, BTX stock has a consensus rating of “Buy” from six analysts.

So let’s check this out.

BioTime Stock

BioTime Inc (NYSE:BTX) is a clinical-stage biotechnology company developing treatments for several degenerative diseases. Headquartered in California, the company’s flagship products include OpRegen, a treatment aimed at macular degeneration of the eye, which is synonymous with the elderly, OPC1, which is a treatment for acute spinal cord injuries, and VAC2, a treatment aimed at non-small cell lung cancer.

OpRegen and OPC1 are both in trial Phase I/IIa, and VAC2 is in Phase I.

BioTime Stock on the Rise

Despite a volatile April, BioTime stock has gained 35.82% since the beginning of the year. Further, it has a consensus price target of $4.86—more than 400% of its current value. Analysts are screaming “Buy” on this stock, and it could be because the company showed promise in its most recent earnings results in March.

The biotechnology company reported $0.07 earnings per share, which matched the consensus estimate. Further, it had revenue of $0.76 million for the quarter, which beat analysts’ expectations of $0.74 million.

STOCKS YOU MAY LIKE

Biotech penny stocks are biotech stocks that sell for less than $5 per share. Most early-stage clinical biotech companies usually fall into the penny stock range. They are prone to market volatility and have large …

In the wake of the coronavirus pandemic, biotech stocks have been of interest to investors, given that they’re some of the top gainers in the past few weeks. In particular, low float biotech stocks have …

Those new to investing in the stock market tend to focus on large cap companies instead of small cap ones. However, Maria Ohle explains that there are plenty of reasons why one should consider investing …

Investors are almost always on the lookout for the latest penny stock gainers, but in the current situation, they need to look into companies far more carefully than before. The coronavirus pandemic has triggered an …

So far in March, stock markets have experienced massive losses as the coronavirus outbreak continues to wreak havoc on the global economy. The Dow Jones and S&P 500 plunged, prompting concerns that a global financial …

Biotech has been one of the fastest-growing sectors over the past half a decade or so, garnering a lot of interest in things like biotech penny stocks. Moreover, the onset of the coronavirus pandemic has …

In 1992, Congress passed the Prescription Drug User Fee Act (PDUFA), which allows the US Food and Drug Administration (FDA) to collect fees from drug manufacturers to fund the drug review and approval process. The …

2019 is almost over, and while some investors are reflecting on a successful year, others are scrambling to add value to their portfolio before the year wraps up. If you didn’t capitalize on the stock …

Despite starting the year off strong, biotech stocks have had a rough summer. The recent weakness in the biotech sector is causing biotech exchange-traded funds (ETFs) like the VanEck Vectors Biotech ETF (BBH), the iShares …

Information provided in this correspondence is intended solely for informational purposes and is obtained from sources believed to be reliable. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained on this website is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions made or suggested and the actual results.

All statements and opinions expressed are the opinions of the author and not of Microsmallcap.com or its officers. The author is wholly responsible for the validity of all statements. Microsmallcap.com was not involved in any aspect of the article preparation. The author was not paid by Market Jar Media Inc for this article. The author did not pay Microsmallcap.com to publish or syndicate this article.

This article does not constitute as investment advice. Each reader is encouraged to consult with his or her individual financial advisor; any and all actions taken by a reader as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Microsmallcap.com's terms of use and full legal disclaimer. This article is in no way a solicitation for investment. Microsmallcap.com does not render general or specific investment advice. Any information on Microsmallcap.com should not be considered a recommendation to buy or sell any security. Microsmallcap.com does not endorse or recommend the business, products, services or securities of any company mentioned on Microsmallcap.com.

Futures, stocks and options trading involves substantial risk of loss and is not suitable for every investor. The valuation of futures, stocks, and options may fluctuate, and, as a result, clients may lose more than their original investment and possibly their entire investment. Any content on this website should not be relied upon as advice or construed as providing recommendations of any kind. It is your responsibility to confirm and decide which trades to make. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Please see our full disclaimer here for additional details before making any investment decisions.